表紙:認知症・アルツハイマー病治療の世界市場 - 業界規模、シェア、動向、機会、予測(2018年~2028年)薬品クラス別、流通チャネル別、地域別、予測、機会(2028年)
市場調査レポート
商品コード
1174496

認知症・アルツハイマー病治療の世界市場 - 業界規模、シェア、動向、機会、予測(2018年~2028年)薬品クラス別、流通チャネル別、地域別、予測、機会(2028年)

Dementia and Alzheimer's Disease Treatment Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Distribution Channel, By Region, Forecast & Opportunities, 2028

出版日: | 発行: TechSci Research | ページ情報: 英文 112 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.96円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

認知症・アルツハイマー病治療の世界市場 - 業界規模、シェア、動向、機会、予測(2018年~2028年)薬品クラス別、流通チャネル別、地域別、予測、機会(2028年)
出版日: 2022年12月01日
発行: TechSci Research
ページ情報: 英文 112 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の認知症・アルツハイマー病治療市場は、2024年~2028年の予測期間中に目覚ましい成長を示すと予測されています。

アルツハイマー病や認知症の患者数の増加と、これらの疾患についての認知度の向上が、市場の成長を促進しています。

当レポートでは、世界の認知症・アルツハイマー病治療市場について調査分析し、市場規模と予測、各地域の見通し、競合情勢などを提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 VOC (顧客の声)

第5章 臨床試験分析

  • 進行中の臨床試験
  • 完了した臨床試験
  • 終了した臨床試験
  • パイプラインの内訳:開発段階別
  • パイプラインの内訳:ステータス別
  • パイプラインの内訳:研究タイプ別
  • パイプラインの内訳:国別
  • 臨床試験ヒートマップ

第6章 世界の認知症・アルツハイマー病治療市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
    • 薬品クラス別(コリン作動性/コリンエステラーゼ(ChE)阻害薬(ドネペジル、ガランタミン、リバスチグミン)、メマンチン、併用薬(メマンチン・ドネペジル))
    • 流通チャネル別(病院薬局、小売薬局、オンライン薬局)
    • 企業別(2022年)
    • 地域別
  • 市場魅力指数

第7章 アジア太平洋の認知症・アルツハイマー病治療市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • アジア太平洋:国別分析
    • 中国の認知症・アルツハイマー病治療市場の見通し
    • インドの認知症・アルツハイマー病治療市場の見通し
    • オーストラリアの認知症・アルツハイマー病治療市場の見通し
    • 日本の認知症・アルツハイマー病治療市場の見通し
    • 韓国の認知症・アルツハイマー病治療市場の見通し

第8章 欧州の認知症・アルツハイマー病治療市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • 欧州:国別分析
    • フランスの認知症・アルツハイマー病治療市場の見通し
    • ドイツの認知症・アルツハイマー病治療市場の見通し
    • 英国の認知症・アルツハイマー病治療市場の見通し
    • イタリアの認知症・アルツハイマー病治療市場の見通し
    • スペインの認知症・アルツハイマー病治療市場の見通し

第9章 北米の認知症・アルツハイマー病治療市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • 北米:国別分析
    • 米国の認知症・アルツハイマー病治療市場の見通し
    • メキシコの認知症・アルツハイマー病治療市場の見通し
    • カナダの認知症・アルツハイマー病治療市場の見通し

第10章 南米の認知症・アルツハイマー病治療市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • 南米:国別分析
    • ブラジルの認知症・アルツハイマー病治療市場の見通し
    • アルゼンチンの認知症・アルツハイマー病治療市場の見通し
    • コロンビアの認知症・アルツハイマー病治療市場の見通し

第11章 中東・アフリカの認知症・アルツハイマー病治療市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
  • 中東・アフリカ:国別分析
    • 南アフリカの認知症・アルツハイマー病治療市場の見通し
    • サウジアラビアの認知症・アルツハイマー病治療市場の見通し
    • アラブ首長国連邦の認知症・アルツハイマー病治療市場の見通し

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の動向と発展

第14章 競合情勢

  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • H. Lundbeck A/S
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Corium, Inc.

第15章 戦略的提言

目次
Product Code: 5058

Global dementia and Alzheimer's disease treatment market is expected to grow at impressive growth during the forecast period, 2024-2028. The increasing cases of Alzheimer's and dementia coupled with growing awareness regarding the diseases are bolstering the growth of the market. Moreover, elderly population are more prone to such diseases due to growing age, which in turn, is expected to positively impact the growth of market. Also, upsurge in R&D activities associated with disease, the introduction of new and innovative technologies and drugs, and increasing government initiatives such as investments, awareness programmes are expected to bolster the growth of market over the next few years. For instance, in 2022, a new initiative by McGill University's Dementia Education Program received funding from the Public Health Agency of Canada to raise awareness of dementia and promote dementia-inclusive communities.

The global dementia and Alzheimer's disease treatment market is segmented into drug class, distribution channel, company and region. Based on drug class, the market is categorized into cholinergic/cholinesterase (ChE) inhibitors, memantine, and combination drugs. Out of these, the cholinergic/cholinesterase (ChE) inhibitor segment dominates the dementia and Alzheimer's disease market. This is accredited to fact that it is first line of treatment for AD and most widely prescribed drug for the treatment. In addition, the drug is very effective for treating mild to severe dementia, which is contributing to the increasing growth of the segment.

The memantine segment is further expected to be the fastest growing segment during the forecast period. This is ascribed to its suitability in cholinergic/cholinesterase inhibitors intolerant patients suffering from AD.

Major players operating in the global dementia and Alzheimer's disease treatment market include Merz Pharma GmbH & Co. KGaA, Novartis AG, Pfizer, Inc., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd., AbbVie Inc., Eli Lilly and Company, and Corium, Inc. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, thereby helping the industry to solve existing challenges and meet the needs of the market.

Objective of the Study

  • To analyze and estimate the market size of global dementia and Alzheimer's disease treatment market from 2018 to 2021.
  • To estimate and forecast the market size of global dementia and Alzheimer's disease treatment market from 2022 to 2028 and growth rate until 2028.
  • To classify and forecast global dementia and Alzheimer's disease treatment market based on drug class, distribution channel, company and regional distribution.
  • To identify dominant region or segment in the global dementia and Alzheimer's disease treatment market.
  • To identify drivers and challenges for global dementia and Alzheimer's disease treatment market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global dementia and Alzheimer's disease treatment market.
  • To conduct pricing analysis for global dementia and Alzheimer's disease treatment market.
  • To identify and analyze the profile of leading players operating in global dementia and Alzheimer's disease treatment market.
  • to identify key sustainable strategies adopted by market players in global dementia and Alzheimer's disease treatment market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals and presence of all major players across the globe.

TechSci Research calculated the market size of global dementia and Alzheimer's disease treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Dementia and Alzheimer's disease treatment facilities and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to dementia and Alzheimer's disease treatment
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global dementia and Alzheimer's disease treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Dementia and Alzheimer's Disease Treatment Market, By Drug Class:

  • Cholinergic/ Cholinesterase Inhibitors
    • Donepezil
    • Galantamine
    • Rivastigmine
  • Memantine
  • Combination Drugs
    • Memantine
    • Donepezil
    • Global Dementia and Alzheimer's Disease Treatment Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Global Dementia and Alzheimer's Disease Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
  • South America
    • Brazil
    • Argentina
    • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global dementia and Alzheimer's disease treatment market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Country
  • 5.8. Clinical Trials Heat Map

6. Global Dementia and Alzheimer's Disease Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Cholinergic/ Cholinesterase (ChE) Inhibitors [Donepezil, Galantamine, Rivastigmine], Memantine, Combination Drugs [Memantine & Donepezil]
    • 6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)
    • 6.2.3. By Company (2022)
    • 6.2.4. By Region
  • 6.3. Market Attractiveness Index

7. Asia-Pacific Dementia and Alzheimer's Disease Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. India Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Australia Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Japan Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. South Korea Dementia and Alzheimer's Disease Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. Europe Dementia and Alzheimer's Disease Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Germany Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. United Kingdom Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. Italy Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Spain Dementia and Alzheimer's Disease Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel

9. North America Dementia and Alzheimer's Disease Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Dementia and Alzheimer's Disease Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Mexico Dementia and Alzheimer's Disease Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Canada Dementia and Alzheimer's Disease Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. South America Dementia and Alzheimer's Disease Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Dementia and Alzheimer's Disease Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Argentina Dementia and Alzheimer's Disease Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Colombia Dementia and Alzheimer's Disease Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Middle East and Africa Dementia and Alzheimer's Disease Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Distribution Channel
    • 11.2.3. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Dementia and Alzheimer's Disease Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Distribution Channel
    • 11.3.2. Saudi Arabia Dementia and Alzheimer's Disease Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Distribution Channel
    • 11.3.3. UAE Dementia and Alzheimer's Disease Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Merz Pharma GmbH & Co. KGaA
  • 14.2. Novartis AG
  • 14.3. Pfizer, Inc.
  • 14.4. Ono Pharmaceutical Co., Ltd.
  • 14.5. Johnson & Johnson Services, Inc.
  • 14.6. H. Lundbeck A/S
  • 14.7. F. Hoffmann-La Roche Ltd.
  • 14.8. AbbVie Inc.
  • 14.9. Eli Lilly and Company
  • 14.10. Corium, Inc.

15. Strategic Recommendations